



11-12-02

GP/1642
HAttorney's Docket No. 35784/209112 (5784-50)PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re: Caligiuri *et al.* Confirmation No.: 8842
Appl. No.: 09/855,342 Group Art Unit: 1642
Filed: May 14, 2001 Examiner: Stephen L. Rawlings
For: METHODS OF THERAPY FOR CANCERS CHARACTERIZED BY
OVEREXPRESSION OF HER2 RECEPTOR PROTEIN

Commissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an AMENDMENT in the above-identified patent application.

- ☐ Applicant claims small entity status. See 37 C.F.R. § 1.27.
☐ No additional fee is required.

The fee has been calculated as shown below:


(COL. 1)		(COL. 2)	(COL. 3)	SMALL ENTITY		OTHER THAN A SMALL ENTITY	
CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEE	OR RATE	ADDIT. FEE
TOTAL	* 39	** 21	= 18	X9=	\$	X18=	\$ 324
INDEP	* 4	*** 3	= 1	X42=	\$	X84=	\$ 84
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				+140=	\$	+280=	\$
				TOTAL ADD FEE \$		OR TOTAL	\$ 408

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior Amendment or the number of claims originally filed.

In re: Caligiuri *et al.*
Appl. No.: 09/855,342
Filed: May 14, 2001
Atty. Dock. No. 35784/209112 (5784-50)
Page 2

- ☐ Please charge my Deposit Account No. 16-0605 in the amount of \$.
- ☒ A check in the amount \$408 to cover the additional fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge any deficiency in payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 16-0605.
- ☒ Any additional filing fees required under 37 C.F.R. § 1.16 for the presentation of extra claims.
- ☒ Any patent application processing fees under 37 C.F.R. § 1.17.

Respectfully submitted,




Leslie T. Henry
Registration No. 45,714
Attorney/Agent of Record

CUSTOMER NO. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

CUSTOMER NO. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

"Express Mail" mailing label number EL 868645730 US
Date of Deposit November 8, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner For Patents, Washington, DC 20231.


Lynda-Jo Pixley



Amend B/#10
11.21.02

Attorney's Docket No. 35784/209112 (5784-50)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Caligiuri *et al.* Confirmation No.: 8842
Appl No.: 09/855,342 Group Art Unit: 1642
Filed: May 14, 2001 Examiner: Stephen L. Rawlings
For: METHODS OF THERAPY FOR CANCERS CHARACTERIZED BY
OVEREXPRESSION OF THE HER2 RECEPTOR PROTEIN

November 8, 2002

Commissioner for Patents
Washington, DC 20231

RECEIVED
NOV 14 2002
TECH CENTER 1600/2900

PRELIMINARY AMENDMENT

Prior to the substantive examination of the above-referenced application on its merits, the Examiner is respectfully requested to enter the following amendments.

In the Claims:

Please cancel claims 1-11 without prejudice to or disclaimer of the subject matter encompassed thereby.

Please amend claims 12, and 14-21 to read as follows:

12. (Amended) A method of treating a cancer characterized by overexpression of the HER2 receptor protein in a subject, said method comprising concurrent therapy with an anti-HER2 antibody or fragment thereof and interleukin-2 (IL-2) or variant thereof, wherein said concurrent therapy comprises administering to said subject at least one therapeutically effective dose of IL-2 or variant thereof in combination with a dosing regimen for said anti-HER2 antibody or fragment thereof, wherein said dosing regimen for said anti-HER2 antibody or fragment thereof comprises administering to said subject at least one therapeutically effective dose of said anti-HER2 antibody or fragment thereof, wherein said therapeutically effective dose of said anti-HER2 antibody or fragment thereof is in the range from about 1.0 mg/kg to about 10.0 mg/kg and wherein said therapeutically effective dose of IL-2 or variant thereof is in the range from about 0.5 mIU/m² to about 4.0 mIU/m².

11/13/2002 HMEKONEN 00000081 09855342

01 FC:1201
02 FC:1202

84.00 OP
324.00 OP

RTA01/2127215v1